Quantbot Technologies LP Akero Therapeutics, Inc. Transaction History

Quantbot Technologies LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$17.76 - $31.18 $19,536 - $34,298	1,100 New	1,100 $27,000
Q4 2022 Feb 13, 2023	BUY	$33.44 - $54.8 $629,273 - $1.03 Million	18,818 New	18,818 $1.03 Million
Q2 2022 Aug 09, 2022	BUY	$8.0 - $15.01 $69,528 - $130,451	8,691 Added 616.82%	10,100 $95,000
Q1 2022 May 16, 2022	SELL	$12.97 - $22.26 $18,988 - $32,588	-1,464 Reduced 50.96%	1,409 $19,000
Q4 2021 Feb 11, 2022	SELL	$19.87 - $26.24 $21,857 - $28,864	-1,100 Reduced 27.69%	2,873 $60,000
Q3 2021 Nov 09, 2021	BUY	$18.65 - $25.46 $62,906 - $85,876	3,373 Added 562.17%	3,973 $88,000
Q2 2021 Aug 12, 2021	BUY	$24.81 - $32.35 $9,924 - $12,940	400 Added 200.0%	600 $14,000
Q3 2020 Nov 16, 2020	BUY	$30.79 - $39.92 $6,158 - $7,984	200 New	200 $6,000

193

74.6M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.52B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.